Clinical research helper WIRB-Copernicus Group (WCG) acquired KMR Group and Metrics Consortium (MCC) in a deal that bolsters the company’s market insights and intelligence division.
Both KMR Group and MCC are focused on clinical trial benchmarking and intelligence. Terms of the acquisitions weren’t disclosed.
“The industry-leading combination of KMR Group and MCC provides our clients unmatched benchmarking data and insights with which to compare their performance with peers,” Donald Deieso, WCG’s chairman and chief executive, said in a statement. “These actionable insights provide clients the advantage of ‘knowing rather than guessing’ in the critical decisions affecting their studies.”
The two latest acquisitions by WCG will operate independently as part of its market insights and intelligence division, the company said.
Last summer, WCG picked up Patient Genesis’ eConsent technology, which features software that uses custom video animations to present clinical trial information and asks patients questions to assess their level of understanding as part of an effort to provide improved patient education and easier enrollment.